A story about adverse reactions, the FDA, the FBI, and patients – Linda Martin, a healthcare executive, shares with Chadi a riveting dialogue about the events in her life that have transpired since she got sick and started taking a standard prescribed antibiotic. Linda tells the story of when and why she was prescribed the antibiotic, how it made her feel worse than before, and how she found similar stories of bad reactions to this drug online. Then, she explains the series of events that led to the stepping-down of the commissioner of the FDA, the FBI’s involvement into investigating drug stock conflicts within the FDA, the stalling of any legal action coming to fruition that may be linked to multiple U.S. presidents, and the suspicious death of the journalist she had been working with to expose the cover-up.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
